Literature DB >> 22330916

Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.

George L Melikian1, Soo-Yon Rhee, Jonathan Taylor, W Jeffrey Fessel, David Kaufman, William Towner, Paolo V Troia-Cancio, Andrew Zolopa, Gregory K Robbins, Ron Kagan, Dennis Israelski, Robert W Shafer.   

Abstract

Determining the phenotypic impacts of reverse transcriptase (RT) mutations on individual nucleoside RT inhibitors (NRTIs) has remained a statistical challenge because clinical NRTI-resistant HIV-1 isolates usually contain multiple mutations, often in complex patterns, complicating the task of determining the relative contribution of each mutation to HIV drug resistance. Furthermore, the NRTIs have highly variable dynamic susceptibility ranges, making it difficult to determine the relative effect of an RT mutation on susceptibility to different NRTIs. In this study, we analyzed 1,273 genotyped HIV-1 isolates for which phenotypic results were obtained using the PhenoSense assay (Monogram, South San Francisco, CA). We used a parsimonious feature selection algorithm, LASSO, to assess the possible contributions of 177 mutations that occurred in 10 or more isolates in our data set. We then used least-squares regression to quantify the impact of each LASSO-selected mutation on each NRTI. Our study provides a comprehensive view of the most common NRTI resistance mutations. Because our results were standardized, the study provides the first analysis that quantifies the relative phenotypic effects of NRTI resistance mutations on each of the NRTIs. In addition, the study contains new findings on the relative impacts of thymidine analog mutations (TAMs) on susceptibility to abacavir and tenofovir; the impacts of several known but incompletely characterized mutations, including E40F, V75T, Y115F, and K219R; and a tentative role in reduced NRTI susceptibility for K64H, a novel NRTI resistance mutation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22330916      PMCID: PMC3346663          DOI: 10.1128/AAC.05487-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  The valine-to-threonine 75 substitution in human immunodeficiency virus type 1 reverse transcriptase and its relation with stavudine resistance.

Authors:  B Selmi; J Boretto; J M Navarro; J Sire; S Longhi; C Guerreiro; L Mulard; S Sarfati; B Canard
Journal:  J Biol Chem       Date:  2000-12-27       Impact factor: 5.157

2.  Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

Authors:  Jeannette M Whitcomb; Neil T Parkin; Colombe Chappey; Nicholas S Hellmann; Christos J Petropoulos
Journal:  J Infect Dis       Date:  2003-09-16       Impact factor: 5.226

3.  An automated genotyping system for analysis of HIV-1 and other microbial sequences.

Authors:  Tulio de Oliveira; Koen Deforche; Sharon Cassol; Mika Salminen; Dimitris Paraskevis; Chris Seebregts; Joe Snoeck; Estrelita Janse van Rensburg; Annemarie M J Wensing; David A van de Vijver; Charles A Boucher; Ricardo Camacho; Anne-Mieke Vandamme
Journal:  Bioinformatics       Date:  2005-08-02       Impact factor: 6.937

4.  Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling.

Authors:  H Vermeiren; E Van Craenenbroeck; P Alen; L Bacheler; G Picchio; P Lecocq
Journal:  J Virol Methods       Date:  2007-06-15       Impact factor: 2.014

5.  Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors.

Authors:  Matthew J Gonzales; Thomas D Wu; Jonathan Taylor; Ilana Belitskaya; Rami Kantor; Dennis Israelski; Sunwen Chou; Andrew R Zolopa; W Jeffrey Fessel; Robert W Shafer
Journal:  AIDS       Date:  2003-04-11       Impact factor: 4.177

6.  Regularization Paths for Generalized Linear Models via Coordinate Descent.

Authors:  Jerome Friedman; Trevor Hastie; Rob Tibshirani
Journal:  J Stat Softw       Date:  2010       Impact factor: 6.440

7.  Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

Authors:  Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

8.  Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Authors:  Atsuko Hachiya; Eiichi N Kodama; Stefan G Sarafianos; Matthew M Schuckmann; Yasuko Sakagami; Masao Matsuoka; Masafumi Takiguchi; Hiroyuki Gatanaga; Shinichi Oka
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

9.  Human immunodeficiency virus reverse transcriptase and protease sequence database.

Authors:  Soo-Yon Rhee; Matthew J Gonzales; Rami Kantor; Bradley J Betts; Jaideep Ravela; Robert W Shafer
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

10.  Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture.

Authors:  S F Lacey; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

View more
  36 in total

1.  In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

Authors:  Zhufang Li; Brian Terry; William Olds; Tricia Protack; Carol Deminie; Beatrice Minassian; Beata Nowicka-Sans; Yongnian Sun; Ira Dicker; Carey Hwang; Max Lataillade; George J Hanna; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

2.  Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa.

Authors:  Kevin D McCormick; Kerri J Penrose; Chanson J Brumme; P Richard Harrigan; Raquel V Viana; John W Mellors; Urvi M Parikh; Carole L Wallis
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

3.  HIV-1 subtypes and drug resistance profiles in a cohort of heterosexual patients in Istanbul, Turkey.

Authors:  Muammer Osman Köksal; Hayati Beka; Nadine Lübke; Jens Verheyen; Haluk Eraksoy; Atahan Cagatay; Rolf Kaiser; Baki Akgül; Ali Agacfidan
Journal:  Med Microbiol Immunol       Date:  2015-04-28       Impact factor: 3.402

4.  Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

Authors:  Michele W Tang; Soo-Yon Rhee; Silvia Bertagnolio; Nathan Ford; Susan Holmes; Kim C Sigaloff; Raph L Hamers; Tobias F Rinke de Wit; Herve J Fleury; Phyllis J Kanki; Kiat Ruxrungtham; Claudia A Hawkins; Carole L Wallis; Wendy Stevens; Gert U van Zyl; Weerawat Manosuthi; Mina C Hosseinipour; Nicole Ngo-Giang-Huong; Laurent Belec; Martine Peeters; Avelin Aghokeng; Torsak Bunupuradah; Sherri Burda; Patricia Cane; Giulia Cappelli; Charlotte Charpentier; Anoumou Y Dagnra; Alaka K Deshpande; Ziad El-Katib; Susan H Eshleman; Joseph Fokam; Jean-Chrysostome Gody; David Katzenstein; Donato D Koyalta; Johnstone J Kumwenda; Marc Lallemant; Lutgarde Lynen; Vincent C Marconi; Nicolas A Margot; Sandrine Moussa; Thumbi Ndung'u; Phillipe N Nyambi; Catherine Orrell; Jonathan M Schapiro; Rob Schuurman; Sunee Sirivichayakul; Davey Smith; Maria Zolfo; Michael R Jordan; Robert W Shafer
Journal:  J Infect Dis       Date:  2013-06-15       Impact factor: 5.226

5.  Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.

Authors:  Robert W Shafer
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

6.  Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.

Authors:  Philip L Tzou; Soo-Yon Rhee; Diane Descamps; Dana S Clutter; Bradley Hare; Orna Mor; Maxime Grude; Neil Parkin; Michael R Jordan; Silvia Bertagnolio; Jonathan M Schapiro; P Richard Harrigan; Anna Maria Geretti; Anne-Geneviève Marcelin; Robert W Shafer
Journal:  J Antimicrob Chemother       Date:  2020-01-01       Impact factor: 5.790

Review 7.  Are subtype differences important in HIV drug resistance?

Authors:  R J Lessells; D K Katzenstein; T de Oliveira
Journal:  Curr Opin Virol       Date:  2012-09-21       Impact factor: 7.090

Review 8.  HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.

Authors:  Kalyan Das; Eddy Arnold
Journal:  Curr Opin Virol       Date:  2013-04-19       Impact factor: 7.090

9.  Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1.

Authors:  Alonso Heredia; Charles E Davis; Marvin S Reitz; Nhut M Le; Mark A Wainberg; James S Foulke; Lai-Xi Wang; Robert R Redfield
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

Review 10.  Intracellular nucleotide levels and the control of retroviral infections.

Authors:  Sarah M Amie; Erin Noble; Baek Kim
Journal:  Virology       Date:  2012-12-20       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.